Zymeworks ( (ZYME) ) has issued an announcement.
Zymeworks Inc. has made significant strides in 2024, marking pivotal advancements in their biotherapeutic pipeline. Key highlights include dosing the first patient in a Phase 1 trial of ZW171 for MSLN-expressing cancers and presenting promising preclinical data on ADC candidates ZW220 and ZW251. Their partner, Jazz Pharmaceuticals, has submitted a New Drug Application for zanidatamab, a HER2-targeting antibody, potentially leading to a U.S. approval for biliary tract cancer. With a robust cash position of $374.9 million, Zymeworks is strategically expanding its focus on innovative therapies, aiming for long-term growth and transformative patient care.
Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.
